1,2
MicroRNAs (miRNAs) 3 are small (approximately 22-nucleotide) RNA molecules that posttranscriptionally regulate protein-coding gene expression by binding to either fully or partially complimentary sequences within target messenger RNA (mRNA). Over 2000 unique miRNAs have been identified in humans (1 ) and these miRNAs can act to either fine tune or markedly alter protein expression of numerous mRNA targets simultaneously, allowing for an enormously complex layer of regulation of cellular pathways. Much interest has focused on the clinical and therapeutic potential of miRNAs, and pharmacological treatments targeting miRNAs are being developed and tested in research trials (2 ) . miRNAs have recently been identified extracellularly in bodily fluids, and differences in peripheral miRNA profiles have been observed in several disease states (3 ). Furthermore, miRNAs have been found to be stable to digestion by ribonucleases (RNAases), repeated freeze-thaw cycles, and prolonged storage (3 ) . These properties mean that extracellular miRNAs may have potential for use in diagnostic and prognostic testing and in personalizing or targeting therapies, as well as enabling identification of novel pathways and molecular mechanisms of disease.
Several previous studies have examined the expression patterns of intracellular miRNAs within adipose tissue and during adipogenesis and have demonstrated their functional significance (4 ) . In this issue of Clinical Chemistry, Ortega et al. (5 ) assessed circulating genomewide miRNA expression in individuals at different levels of obesity and in response to weight loss. The authors found that the expression of several miRNAs in plasma changed significantly with obesity. The authors were also able to identify a signature of miRNAs with a high specificity for morbid obesity. Interestingly, several of the same miRNAs that were regulated in obesity were also identified as changing in the circulation of individuals following weight loss induced by bariatric surgery. However, when weight loss achieved by bariatric surgery was compared with that from a low-calorie diet, the directional changes in plasma miRNA profiles were not reproduced. This finding suggests that these miRNAs are related to the process by which the body weight is lost rather than an effect arising from, for example, a shrinking adipose organ.
The source of circulating miRNAs is not fully understood. In part they may be released from lysed or damaged cells, and some of the circulating miRNAs detected in plasma might originate from hematologic cells (6 ) . However, miRNAs in plasma are surprisingly stable (3 ) despite the presence of RNAases. It has been demonstrated that these miRNAs are protected from degradation by being packaged within small membrane-bound vesicles or bound to RNAbinding proteins.
It currently appears that the majority of miRNAs present within the circulation are protein bound (7, 8 ) to RNA-binding proteins such as the argonaute 2 protein (Ago2) and nucleophosmin 1 (9 ). It is not known whether these complexes are released by dead or dying cells or whether they are actively released. The fact that Ago2 is involved in the functional binding of an miRNA to its target mRNA makes it tempting to speculate that these complexes might be able to enter and function in recipient cells.
Pertinent to the study of circulating miRNAs relating to obesity and weight loss, it has been shown that HDL can also bind miRNAs and can transport them from host to recipient cells (10 ). Vickers et al. (9 ) found that the profiles of miRNAs carried by HDL differed in different disease states and that the miRNA populations associated with HDL were distinct from those contained within exosomes. They also reported that HDL was able to transfer miRNAs to cultured cells, where they were functional and able to affect gene expression. Interestingly, lysosomes containing apolipoprotein A1 have been used to deliver functional siRNA (small interfering RNA) to the liver (11 ) and so it is postulated that HDL bound miRNA may be functional in vivo.
Circulating extracellular vesicles are a heterogeneous population of small membrane-enclosed vesi-cles that are released from cells. They are also termed exosomes or microvesicles, depending on their size and process of genesis, although at present the nomenclature in the literature is inconsistent. It has been demonstrated that they contain specific populations of miRNAs (12 ) and precursor miRNAs (13 ) that are selectively released into the extracellular environment in an energy-dependent manner (9 ) , whereas other miRNAs are retained within the cell. Furthermore, the miRNA populations secreted in extracellular vesicles have been shown to change according to conditions (14 ) . Profiles of miRNAs contained within extracellular vesicles and bound to RNA binding proteins differ, with some miRNAs being specifically associated with one or the other (7 ). The mechanisms by which certain miRNAs are selected for exportation from the cell require further investigation.
Ortega et al. (5 ), although they identified changing miRNA profiles in serum, do not speculate on how these miRNAs are transported. Whether they are protein or HDL bound or contained within exosomes may be of mechanistic relevance. Extracellular vesicles are well described to mediate cell-cell communication by fusing with remote cells and transferring bioactive contents such as DNA, RNA, and cytokines. The finding of miRNA within circulating extracellular vesicles raises the possibility that miRNA may also be transferred to recipient cells. Studies reveal that, at least theoretically, miRNAs contained within extracellular vesicles can act as mediators of cell-cell communication. miRNAs can be taken up by cells in vitro, where they affect gene expression and recipient cell function (12, 14 ) . In nude mice with implanted prostate cancer PC-3M cells, injection of exosomes containing miR-16 into the circulation led to increased abundance of miR-16 in the implanted cells and repression of a luciferase reporter containing a target of miR-16, demonstrating that miRNAs contained within exosomes are also functional in vivo (15 ) . In their study, Ortega et al. (5 ) used in silico methods to identify potential targets of the miRNAs differentially expressed in plasma and demonstrated a correlation with the proposed targets. It certainly does seem possible that miRNAs may be transferred over long distances from donor to recipient cells, where they may be taken up and influence gene expression. Obesity and weight loss are complex and dynamic conditions which effect far more than just the adipose tissue. When studying conditions such as this on an observational, whole-body level, it is almost impossible to say which cells and tissues are responsible for the release of circulating miRNAs and which cells they might target.
In general, far more questions remain unanswered than answered regarding the significance, source, and role of circulating miRNAs. It has been shown that miRNAs are present in the circulation both bound to proteins and contained within extracellular vesicles, that specific miRNA populations are released from cells, and that miRNAs contained within extracellular vesicles can be taken up and function within recipient cells. An attractive hypothesis is that specific cell populations are targeted to take up vesicles containing miRNAs or protein-bound miRNAs from specific donor cells, where they can influence gene expression and in this way act as a targeted signaling mechanism, but this scenario remains speculative and whether or how it might happen is unclear. If true, however, this process would allow for an immensely complex network by which cells could signal one another over great distances and would make it compelling to understand which signaling pathways are being manipulated by plasma-borne miRNAs in obesity and weight loss. It is now important to search for systems for which a functional read-out of circulating miRNAs can be analyzed. This search will inevitably be very challenging because we still know very little about the specificity of the transport route; the site of origin is often unknown and the recipient cell type is most often not known either. Most of the transport vehicles in plasma are of nonspecific nature. With this in mind, we also face uncertainties as to how an miRNA load effective enough to interfere with a recipient cell translation/transcription process can be achieved. In their study, Ortega et al. have taken the first step by identifying changes in circulating miRNAs in obesity and weight loss, but much more work will be required before we can begin to understand the relevance of these findings. Certainly more research into this area is warranted to investigate these interesting questions. 
